GB83 is a potent PAR2 antagonist. GB83 reverses neutrophil elastase-induced synovitis and pain. GB83 blocks the effect of MET-1 supernatant on NG neurons[1].

**IC₅₀ & Target**

**PAR2**

**In Vitro**

GB83 (10 µM) blocks the effect of MET-1 (microbial ecosystem therapeutic-1) supernatant on nodose ganglion (NG) neurons[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

**In Vivo**

GB83 (5 µg; i.p.) reverses neutrophil elastase-induced synovitis and pain in PAR2 KO mice[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

**Animal Model:** 8-14 weeks, 20-30 g male C57Bl/6 mice (PAR2 KO mice)[1]

**Dosage:** 5 µg

**Administration:** I.p.; 3 times at 10 min before and 110 and 230 min after neutrophil elastase administered

**Result:** Significantly blocked the neutrophil elastase induced increase in vascular perfusion, as well as the number of rolling adherent leukocytes, and also significantly attenuated hindpaw alldynia.

**REFERENCES**

